Cite
HARVARD Citation
Espié, P. et al. (2020). First‐in‐human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti‐CD40 monoclonal antibody. American journal of transplantation. 20 (2), pp. 463-473. [Online].